MDLN · XBRL financial data
Medline financial statements, every fiscal year
The same tables from 2 filings, lined up. Matched by XBRL tag: renamed lines keep their history.
How these numbers work
- Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
- Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
- * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
- 0 means a filing states zero; a dash (—) means no filing states that number.
- “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
- Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
- Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
- Shares outstanding come from each filing's cover page, as of the date printed there.
- Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.
Income statement
CSVFiscal years (MDLN's year ends in late December)
| In millions of dollars | Dec 31, 2025 |
|---|---|
| Revenue | 28,432 |
| Cost of goods and services sold | 20,914 |
| Gross profit | 7,518 |
| Research and development | 80 |
| Selling, general and administrative | 4,524 |
| Total operating expenses | 5,306 |
| Other operating income (expense) | (78) |
| Operating income (loss) | 2,212 |
| Interest income | 133 |
| Interest expense | 945 |
| Other income (expense) | (64) |
| Income tax expense (benefit) | 91 |
| Net income (loss) | 1,159 |
| Earnings per share, basic USD per share | (0.01) |
| Earnings per share, diluted USD per share | (0.01) |
| Weighted average shares, basic millions of shares | 810 |
| Weighted average shares, diluted millions of shares | 810 |
Balance sheet
CSVFiscal years (MDLN's year ends in late December)
| In millions of dollars | Dec 31, 2025 |
|---|---|
| Cash and cash equivalents | 1,939 |
| Short-term investments | 0 |
| Accounts receivable | 3,533 |
| Inventory | 4,769 |
| Total current assets | 10,679 |
| Property and equipment, net | 4,778 |
| Right-of-use asset | 432 |
| Goodwill | 8,079 |
| Total assets | 38,484 |
| Accounts payable | 961 |
| Accrued liabilities | 1,452 |
| Current portion of long-term debt | 76 |
| Total current liabilities | 2,490 |
| Long-term debt | 12,484 |
| Lease liability, non-current | 386 |
| Total liabilities | 19,198 |
| Accumulated deficit | (7) |
| Total stockholders' equity | 10,737 |
| Total liabilities and equity | 38,484 |
Cash flows
CSVFiscal years (MDLN's year ends in late December)
| In millions of dollars | Dec 31, 2025 |
|---|---|
| Net income (loss) | 1,159 |
| Stock-based compensation | 76 |
| Depreciation and amortization | 1,011 |
| Net cash from operating activities | 1,744 |
| Purchases of property and equipment | 447 |
| Net cash from investing activities | (474) |
| Share repurchases | 33 |
| Net cash from financing activities | 399 |
| Net change in cash | 1,692 |
Compare with peers
SIC 3841 and related industry codes, similar size. Each row is the latest quarter reported.
How peers are chosen
- SIC 3841 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
- Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
- * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
- A cell reading “not reported” means the filings give no figure for that quarter alone.
| Company | Cash ($M) | Revenue, quarter ($M) | Operating cash flow, quarter ($M) | Shares outstanding | Quarter |
|---|---|---|---|---|---|
| Medline | 2,327 | 7,685 | 715* | not reported | 10-QJun 27, 2026 |
| Solventum | 403 | 2,209 | 227* | 170.2M | 10-QJun 30, 2026 |
| Hologic | 2,168 | 1,048 | 230 | 223.2M | 10-QDec 27, 2025 |
| Align Technology | 1,145 | 1,015 | 183* | 70.5M | 10-QSep 30, 2026 |
| West Pharmaceutical Services | 464 | 875 | 190* | 69.7M | 10-QSep 30, 2026 |
| Baxter International | 1,975 | 2,976 | 558* | 517.3M | 10-QSep 30, 2026 |
| Penumbra | 254 | 410 | 42* | 39.4M | 10-QSep 30, 2026 |
| Zimmer Biomet Holdings | 400 | 2,063 | not reported | 189.3M | 10-QSep 30, 2026 |
| Insulet | not reported | 842 | not reported | 69.4M | 10-QSep 30, 2026 |
Not investment advice. Not affiliated with the U.S. SEC.